Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute.

Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

根据Bernstein的分析，Eli Lilly（LLY）在选举后的下跌可能被夸大了，因为当选总统特朗普的一位亲密盟友似乎支持减肥药物。这家制药公司的股票自选举日以来已下跌超过6%，这也导致了整个行业许多公司股价下跌的部分因素。特朗普宣布将Robert F. Kennedy Jr.任命为领导卫生与公共服务部的候选人后，Eli ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.